17 Results for "

P2Y14R

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "P2Y14R" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-N7114A
CAS No.: 982-57-0
Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N8599
CAS No.: 531-58-8
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC50 values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y14R (IC50 = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .
loading...
    loading...
Cat. No.: HY-162661
CAS No.: 2989271-65-8
Target:  

P2Y Receptor

Research Areas:  

Inflammation/Immunology

P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active P2Y14R antagonist with an IC50 value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis .
loading...
    loading...
Cat. No.: HY-161727
CAS No.: 2728291-29-8
P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .
loading...
    loading...
Cat. No.: HY-172226
Target:  

P2Y Receptor

Research Areas:  

Inflammation/Immunology

P2Y14R antagonist 3 (Compound A) is a potent and orally active P2Y14R antagonist with an IC50 value of 23.60 nM and a Kd value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056)-induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases .
loading...
    loading...
Cat. No.: HY-173407
CAS No.: 3081687-67-1
Research Areas:  

Inflammation/Immunology

P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release .
loading...
    loading...
Cat. No.: HY-161343
CAS No.: 2373280-36-3
Research Areas:  

Inflammation/Immunology

HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function .
loading...
    loading...
Cat. No.: HY-179133
CAS No.: 3021527-82-9
Target:  

P2Y Receptor PKA Raf MEK ERK

Research Areas:  

Inflammation/Immunology

HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .
loading...
    loading...
Cat. No.: HY-156220
CAS No.: 2765570-58-7
MRS4654 is an efficient and neutral P2Y14R (hP2Y14R IC50 = 15.0 nM, mP2Y14R IC50 = 18.6 nM) antagonist. MRS4654 has analgesic and anti-inflammatory effects. MRS4654 can be used for research on asthma and neuropathic pain .
loading...
    loading...
Cat. No.: HY-N7114
CAS No.: 3544-94-3
Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
loading...
    loading...
Cat. No.: HY-110369
CAS No.: 3033550-04-5
Synonyms: a,β-Methylene-2-thio-UDP trisodium
Target:  

P2Y Receptor

Research Areas:  

Inflammation/Immunology

MRS2905 (α,β-Methylene-2-thio-UDP) trisodium is a selective P2Y14R agonist with an EC50 of 0.92 nM. MRS2905 trisodium is inactive at the UDP-activated P2Y6 receptor, and at other P2Y receptors .
loading...
    loading...
Cat. No.: HY-170950
P2Y14 antagonist 1 (compound 45) is a high selective and orally active P2Y14R antagonist with an IC50 of 0.70 nM. P2Y14R antagonist 1 demonstrates significant anti-inflammatory efficacy, effectively mitigating the pulmonary infiltration of immune cells and inflammatory response through suppressing the NLRP3 signaling pathway. P2Y14R antagonist 1 has the potential for the research of acute lung injury .
loading...
    loading...
Cat. No.: HY-178006
Target:  

P2Y Receptor

Research Areas:  

Neurological Disease

MRS4917 is an orally active, potent selective P2Y14 receptor (hP2Y14R) antagonist (IC50 = 2.88 nM, Ki = 1.67 nM) that shows >18,000 fold selectivity against P2Y6R (IC50 = 54 μM). MRS4917 demonstrates oral efficacy in reversing established mechanoallodynia in the chronic constriction injury (CCI) mouse model, while having no effect on thermoregulation. MRS4917 can be used for neurological diseases research .
loading...
    loading...
Cat. No.: HY-131821
CAS No.: 15548-51-3
Synonyms: Thymidine-5'-O-monophosphorothioate
Target:  

P2Y Receptor

Research Areas:  

Others

5'-TMPS (Thymidine-5'-O-monophosphorothioate) is a selective partial agonist of P2Y6R and an antagonist of P2Y14R. Additionally, 5'-TMPS acts as a positive regulator of angiogenesis, exhibiting pro-angiogenic effects
loading...
    loading...
Cat. No.: HY-167855
CAS No.: 2801627-78-9
Target:  

P2Y Receptor

Research Areas:  

Inflammation/Immunology

MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .
loading...
    loading...
Cat. No.: HY-167855S
1’-Epi Gemcitabine hydrochloride- 13C, 15N2 is the 13C- and 15N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .
loading...
    loading...
Cat. No.: HY-N7114AR
CAS No.: 982-57-0
Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
loading...
    loading...
  • 1